BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 21132732)

  • 1. International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens.
    Thapaliya P; Tefferi A; Pardanani A; Steensma DP; Camoriano J; Wu W; Geyer S; Mesa RA
    Am J Hematol; 2011 Jan; 86(1):96-8. PubMed ID: 21132732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcome of pomalidomide therapy in myelofibrosis.
    Begna KH; Pardanani A; Mesa R; Litzow MR; Hogan WJ; Hanson CA; Tefferi A
    Am J Hematol; 2012 Jan; 87(1):66-8. PubMed ID: 22081489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thalidomide therapy for myelofibrosis with myeloid metaplasia.
    Thomas DA; Giles FJ; Albitar M; Cortes JE; Verstovsek S; Faderl S; O'Brien SM; Garcia-Manero G; Keating MJ; Pierce S; Zeldis J; Kantarjian HM
    Cancer; 2006 May; 106(9):1974-84. PubMed ID: 16583431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of low-dose thalidomide and prednisone combined with or without danazol for the treatment of primary myelofibrosis-associated anemia].
    Xu J; Xu Z; Qin T; Li B; Fang L; Zhang H; Hu N; Pan L; Qu S; Zhang Y; Xiao Z
    Zhonghua Xue Ye Xue Za Zhi; 2014 Aug; 35(8):698-702. PubMed ID: 25152115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients.
    Martínez-Trillos A; Gaya A; Maffioli M; Arellano-Rodrigo E; Calvo X; Díaz-Beyá M; Cervantes F
    Ann Hematol; 2010 Dec; 89(12):1233-7. PubMed ID: 20567824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.
    Beksac M; Haznedar R; Firatli-Tuglular T; Ozdogu H; Aydogdu I; Konuk N; Sucak G; Kaygusuz I; Karakus S; Kaya E; Ali R; Gulbas Z; Ozet G; Goker H; Undar L
    Eur J Haematol; 2011 Jan; 86(1):16-22. PubMed ID: 20942865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of the hematologic toxicities of ruxolitinib in patients with MPN-associated myelofibrosis using a combination of thalidomide, stanozolol and prednisone.
    Duan M; Zhou D
    Hematology; 2019 Dec; 24(1):516-520. PubMed ID: 31242816
    [No Abstract]   [Full Text] [Related]  

  • 8. Thalidomide and lenalidomide in primary myelofibrosis.
    Holle N; de Witte T; Mandigers C; Schaap N; Raymakers R
    Neth J Med; 2010 Aug; 68(1):293-8. PubMed ID: 20739725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
    Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P
    J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma.
    Palumbo A; Bertola A; Musto P; Caravita T; Callea V; Nunzi M; Grasso M; Falco P; Cangialosi C; Boccadoro M
    Cancer; 2005 Oct; 104(7):1428-33. PubMed ID: 16116606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thalidomide for the treatment of idiopathic myelofibrosis.
    Strupp C; Germing U; Scherer A; Kündgen A; Mödder U; Gattermann N; Haas R
    Eur J Haematol; 2004 Jan; 72(1):52-7. PubMed ID: 14962263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience.
    Zheng W; Wei G; Ye X; He J; Li L; Wu W; Shi J; Zhang J; Huang W; Xie W; Luo Y; Xue X; Lin M; Huang H; Cai Z
    Leuk Res; 2009 Dec; 33(12):1615-8. PubMed ID: 19773080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S; Stock W; Godwin J; Fisher SG
    Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial.
    Marchetti M; Barosi G; Balestri F; Viarengo G; Gentili S; Barulli S; Demory JL; Ilariucci F; Volpe A; Bordessoule D; Grossi A; Le Bousse-Kerdiles MC; Caenazzo A; Pecci A; Falcone A; Broccia G; Bendotti C; Bauduer F; Buccisano F; Dupriez B
    J Clin Oncol; 2004 Feb; 22(3):424-31. PubMed ID: 14752066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis.
    Thiele J; Kvasnicka HM; Zankovich R; Diehl V
    Haematologica; 2000 Nov; 85(11):1126-34. PubMed ID: 11064463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis.
    Chihara D; Masarova L; Newberry KJ; Maeng H; Ravandi F; Garcia-Manero G; Ferrajoli A; Cortes J; Kantarjian H; Verstovsek S
    Leuk Res; 2016 Sep; 48():1-5. PubMed ID: 27416326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903.
    Mesa RA; Yao X; Cripe LD; Li CY; Litzow M; Paietta E; Rowe JM; Tefferi A; Tallman MS
    Blood; 2010 Nov; 116(22):4436-8. PubMed ID: 20651074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.
    Quintás-Cardama A; Kantarjian HM; Manshouri T; Thomas D; Cortes J; Ravandi F; Garcia-Manero G; Ferrajoli A; Bueso-Ramos C; Verstovsek S
    J Clin Oncol; 2009 Oct; 27(28):4760-6. PubMed ID: 19720904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The efficacy of thalidomide for multiple myeloma: a clinical analysis of 102 Chinese patients].
    Qi PJ; Wang YF; Xu Y; Li YN; Zou DH; Zhao YZ; Xiao ZJ; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):226-9. PubMed ID: 18843974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement of Anaemia in Patients with Primary Myelofibrosis by Low-Dose Thalidomide and Prednisone.
    Bělohlávková P; Maisnar V; Voglová J; Buchler T; Žák P
    Acta Medica (Hradec Kralove); 2016; 59(2):50-3. PubMed ID: 27526305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.